| 发明名称 |
Antibody drug conjugates |
| 摘要 |
The present invention relates to anti-FGFR2 antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer. |
| 申请公布号 |
US9415118(B2) |
申请公布日期 |
2016.08.16 |
| 申请号 |
US201414204023 |
申请日期 |
2014.03.11 |
| 申请人 |
Novartis AG |
发明人 |
Batt David Bryant;Ettenberg Seth Alexander;Haubst Nicole;Hu Tiancen;Jenkins David;Toksoz Engin;Petropoulos Konstantin;Meyer Matthew John |
| 分类号 |
C07K16/00;A61K47/48;A61K45/06;A61K31/496;A61K31/5025;A61K31/662 |
主分类号 |
C07K16/00 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. An antibody drug conjugate of the formula or a pharmaceutically acceptable salt thereof; wherein Ab is an antibody or antigen binding fragment thereof that specifically binds to human FGFR2; wherein the antibody comprises a heavy chain variable region that comprises: (a) a VH CDR1 of SEQ ID NO: 21, (b) a VH CDR2 of SEQ ID NO: 22, (c) a VH CDR3 of SEQ ID NO: 23; and a light chain variable region that comprises: (d) a VL CDR1 of SEQ ID NO: 31, (e) a VL CDR2 of SEQ ID NO: 32, (f) a VL CDR3 of SEQ ID NO: 33, wherein the CDR is defined in accordance with the Kabat definition; and n is an integer from 1 to 10. |
| 地址 |
Basel CH |
